HEALTHCARE RESOURCE UTILIZATION AND REAL-WORLD BURDEN OF ILLNESS IN PATIENTS WITH PD-L1-NEGATIVE METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN THE FIRST-LINE SETTING
Author(s)
Yuanhui Zhang, PhD1, Aiza Malik, MSc2, Kaori L. Ito, PhD3, Natalya Vaksman, PharmD1, Katherine Stang, M.Sc.1, Brian Stwalley, BS, PharmD1, Adam Brufsky, MD, PhD4.
1Gilead Sciences, Inc., Foster City, CA, USA, 2Tempus AI, Inc., Chicago, IL, USA, 3Tempus AI, Inc, Chicago, IL, USA, 4University of Pittsburgh / UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
1Gilead Sciences, Inc., Foster City, CA, USA, 2Tempus AI, Inc., Chicago, IL, USA, 3Tempus AI, Inc, Chicago, IL, USA, 4University of Pittsburgh / UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
OBJECTIVES: To describe healthcare resource utilization (HCRU) and real-world disease burden in patients with PD-L1-negative (PD-L1-) metastatic triple-negative breast cancer (mTNBC) in the first-line (1L) setting.
METHODS: This retrospective cohort study analyzed de-identified mTNBC patient records linked to claims using the Tempus Lens Platform (Tempus AI, Inc., Chicago, IL). Adults with PD-L1- mTNBC who initiated 1L treatment between January 2018 and June 2024 (index date) were included. Patients were followed from index to death, last record, or study end (June 2025), requiring ≥3 months follow-up if alive. Treatment patterns were described. Real-world overall survival (rwOS), progression-free survival (rwPFS), time to next treatment or death (rwTTNTD), and time on treatment (rwToT) were estimated using Kaplan-Meier methods with risk-set adjustment to correct for left truncation. All-cause HCRU was reported per-patient-per-month (PPPM) among a subset of patients with continuous claims enrollment.
RESULTS: 316 patients with PD-L1- mTNBC were included (mean age, 59.7 years; 182 [58%] had recurrent disease, and 16 [9%] received pembrolizumab in the early setting; median follow-up, 16.2 months). In 316 patients who received 1L treatment, 128 (41%) received chemotherapy monotherapy and 105 (33%) received chemotherapy combinations. Among 189 patients who received subsequent lines of therapy, sacituzumab govitecan was used in 2L for 52 (28%) patients and in 3L for 32 (17%) patients. Among patients who received 1L treatment, median rwOS was 17.1 months, rwPFS 5.1 months, rwTTNTD 6.5 months, and rwToT 4.8 months. Among 135 patients eligible for all-cause HCRU analyses, there were 0.88 hospitalizations, 0.21 emergency room visits, 1.98 outpatient medical visits, and 2.55 office visits PPPM.
CONCLUSIONS: Patients with PD-L1- mTNBC experienced suboptimal outcomes and substantial HCRU with heavy reliance on acute medical services, highlighting a significant unmet need in this population.
METHODS: This retrospective cohort study analyzed de-identified mTNBC patient records linked to claims using the Tempus Lens Platform (Tempus AI, Inc., Chicago, IL). Adults with PD-L1- mTNBC who initiated 1L treatment between January 2018 and June 2024 (index date) were included. Patients were followed from index to death, last record, or study end (June 2025), requiring ≥3 months follow-up if alive. Treatment patterns were described. Real-world overall survival (rwOS), progression-free survival (rwPFS), time to next treatment or death (rwTTNTD), and time on treatment (rwToT) were estimated using Kaplan-Meier methods with risk-set adjustment to correct for left truncation. All-cause HCRU was reported per-patient-per-month (PPPM) among a subset of patients with continuous claims enrollment.
RESULTS: 316 patients with PD-L1- mTNBC were included (mean age, 59.7 years; 182 [58%] had recurrent disease, and 16 [9%] received pembrolizumab in the early setting; median follow-up, 16.2 months). In 316 patients who received 1L treatment, 128 (41%) received chemotherapy monotherapy and 105 (33%) received chemotherapy combinations. Among 189 patients who received subsequent lines of therapy, sacituzumab govitecan was used in 2L for 52 (28%) patients and in 3L for 32 (17%) patients. Among patients who received 1L treatment, median rwOS was 17.1 months, rwPFS 5.1 months, rwTTNTD 6.5 months, and rwToT 4.8 months. Among 135 patients eligible for all-cause HCRU analyses, there were 0.88 hospitalizations, 0.21 emergency room visits, 1.98 outpatient medical visits, and 2.55 office visits PPPM.
CONCLUSIONS: Patients with PD-L1- mTNBC experienced suboptimal outcomes and substantial HCRU with heavy reliance on acute medical services, highlighting a significant unmet need in this population.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE549
Topic
Clinical Outcomes, Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology